Cizzle Biotechnology Publishes 2025 Annual Report and Financial Statements

Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has shared an update.

Cizzle Biotechnology Holdings has published its Annual Report and Financial Statements for the year ended 31 December 2025. The document, detailing the company’s financial performance and activities over the period, is now available online through regulatory channels and the company’s website, providing shareholders and other stakeholders with updated transparency on its operations.

The release underlines Cizzle’s continued role in developing and commercialising its CIZ1B-based blood test for early lung cancer detection. By highlighting access to its latest annual financials, the company reinforces its public market obligations and offers the market an opportunity to reassess its progress in leveraging proprietary diagnostics technology through licensing and strategic collaborations.

Spark’s Take on CIZ Stock

According to Spark, TipRanks’ AI Analyst, CIZ is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.

To see Spark’s full report on CIZ stock, click here.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings is a UK-based diagnostics developer focused on early cancer detection. The company has created a non-invasive, cost-effective blood test using its proprietary CIZ1B biomarker technology to detect early-stage lung cancer and pursues royalty-bearing licensing deals and collaborations with leading cancer care centres.

Average Trading Volume: 1,303,678

Technical Sentiment Signal: Buy

Current Market Cap: £10.9M

For detailed information about CIZ stock, go to TipRanks’ Stock Analysis page.